CW February 2005
Volume 14Issue Number 2 February 2005 ISSN 10593802 Yttrium-90 Ibritumomab Tiuxetan Induces High Response in Non-Transplant Patients with Diffuse B-Cell LymphomaYttrium-90 ibritumomab tiuxetan induces high response rates in previously-treated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplantation (ASCT).
Go to Previous Page Go to Next Page Source & Additional Reading F. Morschhauser, 46th Annual Meeting of the American Society of Hematology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
